SpringWorks Therapeutics, Inc.
SWTXDelisted Jul 1, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001773427
SpringWorks Therapeutics, Inc. was delisted on Jul 1, 2025; its insiders filed their last Form 4 on Jul 2, 2025; 223 institutions reported holding it in 13F filings for Q2 2025, worth $3.65B in total; Soros Fund Management was the only superinvestor holding it.
Superinvestors holding SWTX, Q2 2025
1 superinvestor reports holding SpringWorks Therapeutics, Inc. on Form 13F, worth $23.6M in total. Weight is SpringWorks Therapeutics, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2025.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Soros Fund ManagementGeorge Soros | 0.4% | 501,989 | $23.6M | Added+9.9% |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of SWTX each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2025
1 superinvestor holding at quarter end
- Added
- Soros Fund Management (+9.9%)
- Sold out
- Duquesne Family Office, Maverick Capital
Q1 2025
3 superinvestors holding at quarter end
- Reduced
- Duquesne Family Office (−28.4%), Maverick Capital (−84.0%), Soros Fund Management (−23.9%)
Q4 2024
3 superinvestors holding at quarter end
- Added
- Maverick Capital (+4.1%), Duquesne Family Office (+21.9%), Soros Fund Management (+7.4%)
Q3 2024
3 superinvestors holding at quarter end
- Added
- Maverick Capital (+6.8%), Soros Fund Management (+45.3%)
- Reduced
- Duquesne Family Office (−31.0%)
Q2 2024
3 superinvestors holding at quarter end
- New
- Duquesne Family Office
- Added
- Maverick Capital (+36.3%), Soros Fund Management (+88.8%)
Q1 2024
2 superinvestors holding at quarter end
- New
- Soros Fund Management
- Reduced
- Maverick Capital (−33.6%)
Q4 2023
1 superinvestor holding at quarter end
- Added
- Maverick Capital (+350.5%)
Q3 2023
1 superinvestor holding at quarter end